Install
BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe. VIEW ALL FEATURED COMPANIES VIEW ALL FEATURED COMPANIES VIEW ALL FEATURED COMPANIES V
- 342articles · 30d
- 1+ hour agolatest article
- Aug 17, 2026earliest in window
- 92%with images
- 291avg words
- Economy, Business & Finance 196
- Health & Wellness 160
- Medical 158
- Business & Industrial 143
- Finance & Business 132
- Health 75
- Science & Technology 54
- Science & Nature 35
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
TAGRISSO?? (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial
3+ hour, 17+ min ago (605+ words) Longest survival data ever reported in a global Phase III trial in this setting New data reinforce TAGRISSO as the standard of care and backbone therapy in EGFRm lung cancer across stages These results were presented today during the Presidential…...
Retension Pharmaceuticals Appoints LeAnne Bloedon, M.S., RD, as EVP of Clinical Development and Operations, and Kevin Schutz, PharmD, as VP Regulatory Affairs
3+ day, 12+ hour ago (140+ words) Statistics cookies help us to understand how visitors interact with websites by collecting and reporting information anonymously. Marketing cookies allow us to display more relevant ads that are engaging for our users and thereby, they are more valuable for publishers…...
Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
3+ day, 12+ hour ago (194+ words) BioSpace Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced that Bradley Burnam, Chief…...
Drugmakers cherry pick launch regions as MFN creates 'policy environment like an earthquake"
3+ day, 14+ hour ago (406+ words) No more is launching a drug a “straight math exercise,” as Most Favored Nation drug pricing pressures drugmakers to reconsider launch sequences to ensure the best price can be achieved in the main global market: the United States. That’s according…...
Tyra shares slip as bladder cancer responses fall short of investor expectations
3+ day, 14+ hour ago (302+ words) Response rates for Tyra Biosciences’ investigational bladder cancer pill came in below investor expectations, dragging the biotech’s shares down nearly 18%. Tyra is testing the drug candidate, dubbed dabogratinib, in the Phase 2 SURF302 study, focusing on patients with low-grade intermediate-risk non-muscle invasive…...
Ride Therapeutics Announces up to US$7.3 Million Investment from the Cystic Fibrosis Foundation to Advance Next-Generation Genetic Medicines
3+ day, 15+ hour ago (439+ words) BioSpace Ride Therapeutics Announces up to US$7.3 Million Investment from the Cystic Fibrosis Foundation to Advance Next-Generation Genetic Medicines - Investment will support Ride's Molecular Logistics™ platform with the goal of delivering genetic medicines to the lung for all people living…...
For PDUFA VIII, the most valuable incentive may be time
4+ day, 2+ hour ago (506+ words) For a small biotech, the more practical incentive is time. Speed matters—whether a drug succeeds or fails. Finding out earlier that the biology is wrong stops further investment, limits unnecessary exposure of patients and allows scientists and resources to…...
Turn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D., as Chief Scientific Officer
4+ day, 13+ hour ago (238+ words) Dr. Redfield brings more than four decades of experience in immunology, microbiology, infectious disease, clinical research, and public health. He has authored an extensive body of scientific literature cited more than 35,000 times, including research examining cytokine signaling and the biological…...
Solstice rises with $225M to develop next-gen CTLA-4 drug from China
4+ day, 16+ hour ago (303+ words) A new cancer biotech has dawned as Solstice Oncology launches with a massive $225 million Series A fundraising that will be used to advance a CTLA-4 antibody from China’s Harbour BioMed. Solstice CEO Caroline Loew said the mission will be to…...
Caspian launches with $50M, Lilly support to advance disease-modifying diabetes bet
4+ day, 16+ hour ago (197+ words) Caspian Therapeutics has arrived on the biopharma scene, bringing with it $50 million in starting funds, a potentially disease-modifying answer for diabetes and the backing of the industry’s biggest player in metabolic disease, Eli Lilly. The funding push was led by…...